Novo led the sustainable materials producer’s series C round, three years after a round backed by investors including Ginkgo Bioworks.
US-based bioengineering technology provider Genomatica has closed a $118m series C round led by pharmaceutical firm Novo. Casdin Capital, Nicholas Investment Partners, Tenere Capital, Tharsis Capital and Viking Global Investors filled out the participants in the round. Founded in 2000, Genomatica produces sustainable chemicals which leverage plant and waste-derived raw materials to replace traditional materials…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.